ARLINGTON, Va.--(BUSINESS WIRE)--The Medical Device Innovation Consortium (MDIC) announced today that Jo Carol Hiatt, MD, MBA, has joined the organization as Vice President of Health Economics and Patient Value (HEPV). In this role, Dr. Hiatt will facilitate efforts among the Consortium, CMS, private payers and patient advocacy groups to empower medical device companies to better understand the evidence they will need to support efficient CMS review, with the ultimate aim of increasing patient access to innovative medical devices and reducing the cost associated with commercializing these technologies. She joins MDIC following her most recent tenure leading teams to review new technologies to inform evidence-based clinical technology options for Kaiser Permanente, one of America’s leading health care providers and nonprofit health plans. She is a general surgeon and partner emeritus with the Southern California Permanente Medical Group (SCPMG).
“We are looking forward to having Jo Carol join the MDIC team,” said Pamela Goldberg, President and CEO of MDIC. “Not only does she have expertise in how technology adoption decisions are made from the payor perspective, but she also has clinical experience helping patients navigate decision-making processes about their treatment options.”
Dr. Hiatt brings 30+ years of experience working both directly with patients and from the administrative perspective to improve their access to innovative medical care. She has worked closely with FDA, researchers, clinicians, policymakers, and other stakeholders to review and assess health technologies for both public and private coverage. She was a member of the FDA Payor Communication Task Force, former chair of the EXCITE International Payor Advisory Committee, and held advisory roles on various other boards and committees. She served on the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) advising the Administrator of the Centers for Medicare & Medicaid Services (CMS) concerning the adequacy of scientific evidence available to CMS for “reasonable and necessary” determinations under Medicare.
“I am very excited to accept this opportunity supporting MDIC’s efforts accelerating patient access to technologies shown to improve clinical outcomes. I look forward to joining the team,” said Hiatt.
About the Medical Device Innovation Consortium
Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to promote public health through science and technology and to enhance trust and confidence among stakeholders. MDIC works in the pre-competitive space to facilitate the development of methods, tools, and approaches that enhance understanding and improve evaluation of product safety, quality, and effectiveness. Its initiatives aim to improve product safety and patient access to cutting-edge medical technology while reducing cost and time to market. For more information, visit http://www.mdic.org.